Drug Profile
Research programme: monoclonal antibodies mimicking T cell receptors - Agenus/Pure MHC
Latest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator PhosImmune; Pure MHC
- Developer Agenus; Pure MHC
- Class Antineoplastics; Cancer vaccines; Heat shock proteins; Immunotherapies; Monoclonal antibodies; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Cancer (Late-stage disease) in USA (Parenteral)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer(Late-stage disease) in USA (Parenteral)
- 16 Mar 2018 Agenus has issued and pending patents for phosphorylated antigenic targets in USA